Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Revumenib in Treating Patients with Relapsed or Refractory Leukemia Associated with Upregulation of HOX Genes

Trial Status: active

This phase II trial tests how well revumenib works in treating patients with leukemia that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) and the disease has genetic mutations (changes) related to an increase in expression of HOX genes. HOX genes are responsible for the immature state of leukemia cells. Revumenib works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving revumenib may help control leukemias associated with an increase in expression of HOX genes.